Fischer M, Vetter W, Winterberg B, Vetter H
Nuklearmedizin. 1984 Apr;23(2):77-9.
In 91 patients with a suspicion of pheochromocytoma 96 scintigraphies with 131I-metaiodobenzylguanidine were performed. The distribution of this radiopharmaceutical agent was studied. In about 71% we found uptake in the liver, in about 20% in the spleen and in about 6% in the gastrointestinal tract. In 13% of our patients a normal tracer uptake in the adrenal medulla was observed. In 23 patients adrenal or extra-adrenal lesion(s) were localized correctly, whereas one false-positive and one false-negative scintigramme was obtained. The 131I-MIBG imaging of adrenal and extra-adrenal, benign and malignant pheochromocytomas and adrenomedullary hyperplasia is highly specific. In the treatment of pheochromocytomas more experience is needed to present final results, but especially in malignant pheochromocytomas 131I-MIBG therapy may be useful.
对91例疑似嗜铬细胞瘤患者进行了96次131I-间碘苄胍闪烁扫描。研究了这种放射性药物的分布情况。约71%的患者肝脏有摄取，约20%的患者脾脏有摄取，约6%的患者胃肠道有摄取。13%的患者肾上腺髓质示踪剂摄取正常。23例患者的肾上腺或肾上腺外病变定位正确，而获得了1例假阳性和1例假阴性闪烁扫描图。肾上腺和肾上腺外、良性和恶性嗜铬细胞瘤以及肾上腺髓质增生的131I-MIBG成像具有高度特异性。在嗜铬细胞瘤的治疗中，需要更多经验才能得出最终结果，但131I-MIBG治疗尤其对恶性嗜铬细胞瘤可能有用。
